Abstract |
Efficacy and tolerability of atorvastatin (20 mg/day) were assessed in a 3 month study on 19 patients (5 men, 14 women, mean age 52.3 years) with familial hypercholesterolemia. Average baseline levels of total cholesterol (CH) and low density lipoprotein ( LDL) CH were 10.7 and 8.6 mmol/l, respectively. By the end of 3 months levels of CH, LDL CH, triglycerides and atherogeneity index decreased by 32, 41, 16 and 45%, respectively. This was accompanied by 21% increase of high density lipoprotein CH level. There were no cases of AST or ALT activity elevation above 3 upper limits of normal values. However 1 patient had asymptomatic elevation of ALT activity up to 53 U/l which did not cause interruption of therapy. Creatine kinase remained normal throughout the study period. Three patients (16%) stopped taking atorvastatin because of side effects. Thus in patients with familial hypercholesterolemia the dose of atorvastatin 20 mg/day was sufficiently well tolerated and provided effective control of lipid levels.
|
Authors | A V Susekov, T V Balakhonova, O A Pogorelova, Z A Aligisheeva, V N Titov, O Iu At'kov, V V Kukharchuk |
Journal | Kardiologiia
(Kardiologiia)
Vol. 43
Issue 8
Pg. 36-9
( 2003)
ISSN: 0022-9040 [Print] Russia (Federation) |
Vernacular Title | Atorvastatin pri lechenii bol'nykh s nasledstvennoĭ giperkholesterinemieĭ. |
PMID | 14593381
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anticholesteremic Agents
- Heptanoic Acids
- Lipoproteins
- Pyrroles
- Atorvastatin
|
Topics |
- Adult
- Anticholesteremic Agents
(adverse effects, therapeutic use)
- Atorvastatin
- Female
- Heptanoic Acids
(adverse effects, therapeutic use)
- Humans
- Hyperlipoproteinemia Type II
(blood, drug therapy)
- Lipoproteins
(blood)
- Male
- Middle Aged
- Pyrroles
(adverse effects, therapeutic use)
- Treatment Outcome
|